Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Review of Immune-Mediated Adverse Events in Melanoma

A Review of Immune-Mediated Adverse Events in Melanoma The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Review of Immune-Mediated Adverse Events in Melanoma

Kennedy, Lucy; Salama, April
Oncology and Therapy , Volume 7 (2) – Jul 8, 2019
Download PDF
20 pages

Loading next page...
 
/lp/springer-journals/a-review-of-immune-mediated-adverse-events-in-melanoma-W1Hd7qCqBF
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-0096-8
Publisher site
See Article on Publisher Site

Abstract

The use of checkpoint inhibitor-based immunotherapy has transformed the treatment landscape for melanoma as well as many other cancer types. With the ability to potentiate tumor-specific immune responses, these agents can result in durable tumor control. However, this activation of the immune system can lead to a unique constellation of side effects, distinct from other cancer therapies, collectively termed immune-mediated adverse events (irAEs). This review will focus on irAEs and guidelines for management related to the most clinically relevant checkpoint inhibitors, those that target programmed death receptor-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4).

Journal

Oncology and Therapy – Springer Journals

Published: Jul 8, 2019

References

  • The blockade of immune checkpoints in cancer immunotherapy
    Pardoll, DM
  • Cancer immunotherapy comes of age
    Mellman, I; Coukos, G; Dranoff, G
  • Improved survival with ipilimumab in patients with metastatic melanoma
    Hodi, FS; O’Day, SJ; McDermott, DF
  • Pembrolizumab versus ipilimumab in advanced melanoma
    Robert, C; Schachter, J; Long, GV
  • Nivolumab in previously untreated melanoma without BRAF mutation
    Robert, C; Long, GV; Brady, B
  • Immune-related adverse events associated with immune checkpoint blockade
    Postow, MA; Sidlow, R; Hellmann, MD
  • Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade
    Esfahani, K; Miller, WH
  • Fulminant myocarditis with combination immune checkpoint blockade
    Johnson, DB; Balko, JM; Compton, ML
  • Immune and molecular correlates in melanoma treated with immune checkpoint blockade
    Byrne, EH; Fisher, DE
  • Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production
    Feng, T; Qin, H; Wang, L; Benveniste, EN; Elson, CO; Cong, Y
  • Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
    Tarhini, AA; Zahoor, H; Lin, Y
  • Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
    Iwama, S; Remigis, A; Callahan, MK; Slovin, SF; Wolchok, JD; Caturegli, P
  • Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series
    Caturegli, P; Dalmazi, G; Lombardi, M
  • Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
    Osorio, JC; Ni, A; Chaft, JE
  • Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
    Puzanov, I; Diab, A; Abdallah, K
  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Haanen, J; Carbonnel, F; Robert, C
  • Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, JR; Lacchetti, C; Schneider, BJ
  • New NCCN guidelines: recognition and management of immunotherapy-related toxicity
    Thompson, JA
  • Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
    Bertrand, A; Kostine, M; Barnetche, T; Truchetet, ME; Schaeverbeke, T
  • Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
    Wang, Y; Zhou, S; Yang, F
  • Overall survival with combined nivolumab and ipilimumab in advanced melanoma
    Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R
  • Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma
    Shoushtari, AN; Friedman, CF; Navid-Azarbaijani, P
  • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    Wolchok, JD; Neyns, B; Linette, G
  • Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
    Villadolid, J; Amin, A
  • Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy
    Kumar, V; Chaudhary, N; Garg, M; Floudas, CS; Soni, P; Chandra, AB
  • Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Belum, VR; Benhuri, B; Postow, MA
  • Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab
    Hua, C; Boussemart, L; Mateus, C
  • Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J; Page, DB; Li, BT
  • Immune checkpoint inhibitor toxicity
    Palmieri, DJ; Carlino, MS
  • Cutaneous adverse effects of the immune checkpoint inhibitors
    Collins, LK; Chapman, MS; Carter, JB; Samie, FH
  • Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort
    Hwang, SJ; Carlos, G; Wakade, D
  • Management of immune-related adverse events and kinetics of response with ipilimumab
    Weber, JS; Kahler, KC; Hauschild, A
  • Systematic review: colitis associated with anti-CTLA-4 therapy
    Gupta, A; Felice, KM; Loftus, EV; Khanna, S
  • Gastrointestinal and hepatic complications of immune checkpoint inhibitors
    Cramer, P; Bresalier, RS
  • Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies
    Chen, JH; Pezhouh, MK; Lauwers, GY; Masia, R
  • Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
    Bergqvist, V; Hertervig, E; Gedeon, P
  • Emerging role of vedolizumab in managing refractory immune checkpoint inhibitor-induced enteritis
    Diana, P; Mankongpaisarnrung, C; Atkins, MB; Zeck, JC; Charabaty, A
  • A Randomized, double-blind, placebo-controlled, phase ii study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
    Weber, J; Thompson, JA; Hamid, O
  • Management of toxicities of immune checkpoint inhibitors
    Spain, L; Diem, S; Larkin, J
  • Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma
    Weber, JS; Hodi, FS; Wolchok, JD
  • Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy
    Chmiel, KD; Suan, D; Liddle, C
  • Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis
    Barroso-Sousa, R; Barry, WT; Garrido-Castro, AC
  • Immune-related adverse events with immune checkpoint blockade: a comprehensive review
    Michot, JM; Bigenwald, C; Champiat, S
  • Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
    Weber, JS; Dummer, R; Pril, V; Lebbé, C; Hodi, FS
  • Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
    Ryder, M; Callahan, M; Postow, MA; Wolchok, J; Fagin, JA
  • Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review
    Friedman, CF; Proverbs-Singh, TA; Postow, MA
  • A rare case of thyroid storm
    McMillen, B; Dhillon, MS; Yong-Yow, S
  • Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
    Morganstein, DL; Lai, Z; Spain, L
  • Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy
    Eggermont, AM; Chiarion-Sileni, V; Grob, JJ
  • Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
    Ascierto, PA; Vecchio, M; Robert, C
  • Toxicities of immunotherapy for the practitioner
    Weber, JS; Yang, JC; Atkins, MB; Disis, ML
  • Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
    Sznol, M; Postow, MA; Davies, MJ
  • Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies
    Byun, DJ; Wolchok, JD; Rosenberg, LM; Girotra, M
  • Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study
    Min, L; Hodi, FS; Giobbie-Hurder, A
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Naidoo, J; Wang, X; Woo, KM
  • Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
    Delaunay, M; Cadranel, J; Lusque, A
  • Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis
    Lomax, AJ; McGuire, HM; McNeil, C
  • Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission
    Vogel, WV; Guislain, A; Kvistborg, P; Schumacher, TN; Haanen, JB; Blank, CU
  • Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature
    Cappelli, LC; Gutierrez, AK; Bingham, CO; Shah, AA
  • Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer
    Suarez-Almazor, ME; Kim, ST; Abdel-Wahab, N; Diab, A
  • Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade
    Naidoo, J; Cappelli, LC; Forde, PM
  • Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment
    Belkhir, R; Burel, SL; Dunogeant, L
  • Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
    Cappelli, LC; Gutierrez, AK; Baer, AN
  • Neurological adverse events associated with immune checkpoint inhibitors: review of the literature
    Cuzzubbo, S; Javeri, F; Tissier, M
  • Neurologic complications of immune checkpoint inhibitors
    Hottinger, AF
  • Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
    Liao, B; Shroff, S; Kamiya-Matsuoka, C; Tummala, S
  • Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma
    Vallet, H; Gaillet, A; Weiss, N
  • Neurological toxicities associated with immune-checkpoint inhibitors
    Touat, M; Talmasov, D; Ricard, D; Psimaras, D
  • Adverse renal effects of immune checkpoint inhibitors: a narrative review
    Wanchoo, R; Karam, S; Uppal, NN
  • Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
    Cortazar, FB; Marrone, KA; Troxell, ML
  • Ocular and orbital side-effects of checkpoint inhibitors: a review article
    Antoun, J; Titah, C; Cochereau, I
  • Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis
    Lurz, P; Eitel, I; Adam, J
  • Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
    Laubli, H; Balmelli, C; Bossard, M; Pfister, O; Glatz, K; Zippelius, A
  • Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab
    Tadokoro, T; Keshino, E; Makiyama, A
  • Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
    Heinzerling, L; Ott, PA; Hodi, FS
  • Cardiotoxicity of immune checkpoint inhibitors
    Varricchi, G; Galdiero, MR; Marone, G
  • Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
    Shiuan, E; Beckermann, KE; Ozgun, A
  • Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
    Helgadottir, H; Kis, L; Ljungman, P
  • Autoimmune hemolytic anemia as a complication of nivolumab therapy
    Palla, AR; Kennedy, D; Mosharraf, H; Doll, D
  • Hemophilia A induced by ipilimumab
    Delyon, J; Mateus, C; Lambert, T
  • Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient
    Pellegrino, B; Musolino, A; Tiseo, M
  • Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
    Kong, BY; Micklethwaite, KP; Swaminathan, S; Kefford, RF; Carlino, MS
  • Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
    Stroud, CR; Hegde, A; Cherry, C
  • Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series
    Kim, ST; Tayar, J; Trinh, VA
  • Rheumatoid arthritis: tocilizumab and the risk of intestinal perforation
    Shipman, L
  • Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial
    Lebbe, C; Meyer, N; Mortier, L
  • Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
    Long, GV; Atkinson, V; Cebon, JS
  • Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy
    Sun, J; Schiffman, J; Raghunath, A; Ng Tang, D; Chen, H; Sharma, P
  • Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy
    Lim, SY; Lee, JH; Gide, TN
  • Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders
    Johnson, DB; Sullivan, RJ; Ott, PA
  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
    Menzies, AM; Johnson, DB; Ramanujam, S
  • Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease
    Abdel-Wahab, N; Shah, M; Lopez-Olivo, MA; Suarez-Almazor, ME
  • Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
    Pollack, MH; Betof, A; Dearden, H
  • Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo
    Ito, T; Ueno, T; Clarkson, MR
  • Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner
    Zhang, T; Fresnay, S; Welty, E
  • PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection
    Tanaka, K; Albin, MJ; Yuan, X
  • Role of the PD-1 pathway in the immune response
    Riella, LV; Paterson, AM; Sharpe, AH; Chandraker, A
  • Immune checkpoint inhibitors in organ transplant patients
    Kittai, AS; Oldham, H; Cetnar, J; Taylor, M
  • Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options
    Velu, V; Shetty, RD; Larsson, M; Shankar, EM
  • Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy
    Gay, CL; Bosch, RJ; Ritz, J
  • Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer - a phase 1 study
    Uldrick, TS; Goncalves, PH; Abdul-Hay, M
  • Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1 infected
    González-Cao, M; Moran, T; Dalmau, J
  • Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review
    Cook, MR; Kim, C
  • Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients
    Heppt, MV; Schlaak, M; Eigentler, TK